- Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
- Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
- Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
- Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
- Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
- Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
- Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
- Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
More ▼
Key statistics
On Friday, Silo Pharma Inc (SILO:NAQ) closed at 0.9626, 7.89% above its 52-week low of 0.8922, set on Jul 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.00 |
---|---|
High | 1.02 |
Low | 0.8922 |
Bid | 0.932 |
Offer | 0.9558 |
Previous close | 0.955 |
Average volume | 96.45k |
---|---|
Shares outstanding | 3.69m |
Free float | 3.47m |
P/E (TTM) | -- |
Market cap | 3.55m USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 20:58 BST.
More ▼